4592 — SanBio Share News
0.000.00%
Table: Sanbio -Q1 group results
Table: Sanbio -2018/19 group results
Table: Sanbio -2018/19 parent results
Brief: Sumitomo Dainippon Pharma, SanBio Say Phase 2B Study In U.S. Evaluating SB623 Did Not Meet Primary Endpoint
Table: Sanbio -2018/19 group forecast
Table: Sanbio - 9-MTH group results
Table: Sanbio - 6-MTH group results
Brief: SanBio forms business and capital alliance with CareNet, Vital Ksk Holdings, Medical Incubator Japan and ASTEM
Brief: Sanbio Group Announced Acquisition Of A Patent Portfolio Regarding Cell Medicines Derived From Mesenchymal Stem Cells
Table: Sanbio Company Limited -2018 6-month group forecast
Table: Sanbio -Q1 group results
Brief: SanBio says exercise of options
Brief: SanBio says exercise of options
Brief: SanBio says exercise of options
Brief: SanBio announces exercise of options
Brief: SanBio says exercise of options
Brief: SanBio announces exercise of options
Brief: SanBio says business alliance with Hitachi Chemical and its unit on manufacturing of SB623
Table: Sanbio -2017/18 group results